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TObjective: Several studies have suggested that positron emission tomography is
more accurate than computed tomography for the staging of non–small cell lung
cancer and can reduce the rate of unnecessary thoracotomy in patients with poten-
tially resectable disease. However, there are few data on the utility of positron
emission tomography in the diagnosis of patients with tumors of 2 cm or less in size.
Methods: Patients with cT1/cT2 tumors of 2 cm or less in size were retrospectively
reviewed. All had a computed tomographic scan, as well as a positron emission
tomographic scan on a dedicated scanner, with a standard uptake value reported. A
standard uptake value of 2.5 g/mL or greater was considered positive. The results of
computed tomography and positron emission tomography were correlated with
pathologic results after either resection (n  60) or mediastinoscopy (n  4).
Results: Sixty-four patients (38 women; mean age, 66 years) had a mean tumor size
of 1.4 cm (range, 0.7-2.0 cm). Forty-three patients had adenocarcinoma, 13 had
adenocarcinoma–bronchioloalveolar carcinoma, 5 had squamous cell carcinoma,
and 3 had other tumor types. Twenty-nine (45%) tumors had negative positron
emission tomographic results. Both tumor size (1 cm vs 1 cm) and cell type
(adenocarcinomabronchioloalveolar carcinoma vs all other cell types) were sig-
nificant predictors of positron emission tomography uptake in the primary tumor
(P .05 and .01, respectively). Nodal metastases were detected pathologically in 11
(17%) patients (5 N1 and 6 N2). Positron emission tomographic sensitivity and
specificity for nodal metastases were only 45% and 89%, respectively. There was no
statistically demonstrable survival difference between positron emission tomog-
raphy–positive and positron emission tomography–negative tumors (3-year survival
of 87% vs 100%, respectively).
Conclusion: Positron emission tomographic scanning has no demonstrable benefit in
the diagnosis, staging, or prognosis of patients with tumors of 2 cm or less in size.
Positron emission tomographic (PET) scanning has been shown to be accuratein the diagnosis and staging of non–small cell lung cancer (NSCLC).1-6 PETscanning is superior to conventional computed tomographic (CT) scanning in
staging mediastinal lymph nodes, with a reported average sensitivity and specificity
for PET of 80% and 90%, respectively.7 In addition, PET scanning has demon-
strated accuracy in determining the extent of extrathoracic disease, such as bone,
adrenal, and hepatic metastases.8-10 Recently, both the American College of Sur-
geons Trial (ACOSOG Z0050) trial and the PET in Lung Cancer Staging trial
determined that PET appeared to reduce the incidence of unwarranted thoracoto-
mies.11,12 Based in large part on these studies, PET scanning has become a routine
component of the preoperative evaluation of patients with NSCLC.
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TSOver the past decade, the increased use of CT scanning
has resulted in a relative decrease in the median tumor size
of resected NSCLC,13 yet little is known in regard to the
utility of PET in the diagnosis and staging of such small
lesions. None of the aforementioned trials focused on pa-
tients with tumors of 2 cm or less in size. We performed a
retrospective analysis to determine the role of PET in T1 or
T2 NSCLC of 2 cm or less in size.
Patients and Methods
Patient Population
We conducted a retrospective review of all patients with primary
tumors of 2 cm or less in size from our thoracic surgery cancer
database at the Weill Medical College of Cornell University. We
included patients with NSCLC of 2 cm or less in size who had a
mediastinoscopy alone or a lobectomy with a mediastinal node
dissection between 2001 and 2004. All had a single tumor of 2 cm
or less determined by means of CT measurement, no history of
cancer in the previous 5 years, and a PET scan performed on a
dedicated scanner, with a standard uptake value (SUV) reported.
We excluded patients who had prior neoadjuvant chemotherapy,
those presenting with ground-glass opacities, or those found to
have bronchioloalveolar carcinoma (BAC) or well-differentiated
neuroendocrine carcinoma on final histology.
Staging
All patients were evaluated preoperatively on the basis of a com-
plete history and physical examination, a CT scan of the chest and
upper abdomen, and a PET scan. Brain scanning was obtained if
clinically indicated. A clinical TNM stage was then determined.
All CT scan reports, actual films, or both were reviewed, and
exact tumor size and nodal status were determined. Tumors were
classified as central or peripheral when possible. We defined a
peripheral tumor as one lying in the outer one third of the lung
parenchyma. Enlarged mediastinal lymph nodes were defined as
lymph nodes greater than 1 cm in the short axis. PET scans were
obtained at facilities with a dedicated PET scanner, and only those
reports that provided an actual maximum SUV were used for this
study. We defined a maximum SUV of 2.5 g/mL or higher as a
positive reading.14 Pathologic staging was obtained either after
resection with mediastinal lymph node dissection or after
mediastinoscopy.
Statistical Analysis
The associations between PET uptake and tumor size (1 cm vs
Abbreviations and Acronyms
BAC  bronchioloalveolar carcinoma
CT  computed tomography
FDG  fluorodeoxyglucose
NSCLC non–small cell lung cancer
PET  positron emission tomography
SUV  standard uptake value1 cm) and between PET uptake and cell type (other vs BAC)
1612 The Journal of Thoracic and Cardiovascular Surgery ● Decwere explored by using the Pearson 2 test. Patient survival was
analyzed with Kaplan-Meier product-limit estimation. The inde-
pendent effect of tumor size as a continuous variable on PET
uptake was examined by using Pearson correlation and a multiva-
riable linear regression analysis. All P values were 2 sided, with
statistical significance evaluated at the .05  level. All analyses
were performed with SPSS version 11.0.3 software (SPSS Inc,
Chicago, Ill). This study was approved by the Institutional Review
Board of the Weill Medical College of Cornell University.
Results
Patient Population
During the study period, 222 patients underwent either
resection or mediastinoscopy for tumors of 2 cm or less in
size. One hundred forty of these patients had a preoperative
PET scan, of whom 83 had dedicated PET scans with SUV
data. Fourteen patients with ground-glass opacities and 5
with multiple nodules were excluded. Therefore the final
study population consisted of 64 patients, 60 after primary
resection and 4 after a positive mediastinoscopy alone.
Patient demographics and tumor characteristics are depicted
in Table 1. Sixty-four patients (38 women; mean age, 66
TABLE 1. Demographics and clinicopathologic character-
istics
n %
Age (y) Mean 65.94 (46-81)
Sex
F 38 59.4
M 26 40.6
Smoking status
Smoker 56 87.5
Nonsmoker 6 9.4
Unknown 2 3.1
Tumor location
Central 6 9.0
Peripheral 44 68.0
NA 14 22.0
Tumor size (cm)
Mean 1.395
Range 0.7-2.0
1 cm 9 14.9
1-2.0 cm 55 85.9
Histology
Adenocarcinoma 43 67.2
Adenocarcinoma-BAC 13 20.3
Squamous carcinoma 5 7.8
NSCLC NOS 1 1.6
Large cell 1 1.6
Poorly differentiated 1 1.6
T1:T2 *52:7
NA, Not available; BAC, bronchioloalveolar carcinoma; NSCLC, non–small
cell lung cancer; NOS, not otherwise specified. *One patient with T4
disease and 4 patients with mediastinoscopy only.years) had a mean tumor size of 1.4 cm (0.7-2.0 cm).
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TSForty-three patients had adenocarcinoma, thirteen had ade-
nocarcinoma with BAC features, 5 had squamous cell car-
cinoma, and 3 had other tumor types.
Thirty-five tumors were PET positive (55%), whereas 29
(45%) were not fluorodeoxyglucose (FDG) avid (Table 2).
Both tumor size (1 cm vs 1 cm: 61% vs 31%, P  .05)
and cell type (adenocarcinoma-BAC vs all other cell types:
63% vs 23%, P  .01) were found to be significant predic-
tors of positive PET uptake (SUV  2.5) by means of the
Pearson 2 test. The analysis was repeated for both tumor
size and cell type with an SUV cutoff of 2.0 g/mL, and the
results were essentially unchanged (data not shown). When
analyzed as continuous variables by using Pearson correlation,
tumor size and SUV showed a significant association ( 0.3,
P  .05). When tumor size was analyzed by means of multi-
variable linear regression with age, sex, histology, and patho-
logic stage as covariables, it was a significant independent
predictor of SUV (b  2.7, P  .02; Table 3).
Nodal metastases were detected pathologically in 11
(17%) patients (5 N1 and 6 N2). PET sensitivity and spec-
ificity for nodal metastases was 45% and 89%, respectively
(Table 4). Of the 6 patients with a false-negative PET scan
for nodal disease, 4 had a positive PET scan and 2 had a
false-negative scan in the primary tumor. Also, only one
TABLE 2. PET results
PET
Positive n  35 54.7%
Negative n  29 45.3%
Maximum SUV (mean) 4.04
Maximum SUV (range) 0.9-16.0
PET () by size
1 cm 4/9 44.4%
1-2.0 cm 31/55 56.4%
PET () by cell type
Adenocarcinoma 25/43 58%
Adenocarcinoma/BAC 3/13 23%
Squamous carcinoma 5/5 100%
Other 2/3 66%
PET, Positron emission tomography; SUV, standard uptake value; BAC,
bronchioloalveolar carcinoma.
TABLE 3. Multivariable regression analysis
Factor b t P value
Constant 2.97 0.93 .36
Age 0.044 1.01 .32
Sex 0.96 1.10 .28
Histology (other, BAC) 1.47 1.25 .22
Pathologic stage(IA,
non-IA)
0.035 0.04 .97
Pathologic tumor size 2.67 2.42 .02BAC, Bronchioloalveolar carcinoma.
The Journal of Thoracicpatient with a false-negative PET scan in the mediastinum
had an adenocarcinoma with a BAC component.
Although the study was not intended to evaluate the
accuracy of CT scanning for nodal staging, the overall
sensitivity and specificity for N1 and N2 disease combined
was 36% and 100%, respectively (Table 5). There was no
statistically demonstrable survival difference between PET-
positive and PET-negative tumors (3-year survival of 87%
vs 100%, respectively; Figure 1). However, there are too
few patients in this study to detect a small but potentially
real difference in survival between these 2 groups.
Discussion
PET is a relatively new technology that holds the promise of
improved accuracy in the diagnosis and staging of patients
with NSCLC.7,15 As a result of numerous reports proclaim-
ing the benefit of PET, it has become widely adopted as the
standard of care for the evaluation of patients with NSCLC,
regardless of clinical stage. However, the role of PET scan-
ning in the diagnosis and staging of small (2 cm) NSCLC
has not been thoroughly examined.
In the current report, which is primarily composed of pe-
ripherally located small adenocarcinomas (68%), only 55% of
these tumors were FDG avid, despite the exclusion of patients
with pure BAC, lesions known not to accumulate FDG.
These data are applicable to tumors larger and smaller
than 1.0 cm in size and have obvious implications for the
use of PET as the definitive diagnostic procedure for pe-
ripheral pulmonary nodules that otherwise appear clinically
suspicious. Multiple studies have shown an improved effi-
cacy with PET compared with conventional CT for the
evaluation of mediastinal lymph nodes.7,11,14 PET sensitiv-
ity and specificity are consistently reported in the 80%
range, yet in this analysis PET sensitivity for the detection
of N1 or N2 disease was 45%, with a specificity of 89%.
TABLE 4. Comparison of PET and pathologic N (pN) stages
(n  64)
pN0 pN1 pN2 Total
PET N0 47 4 2 53
PET N1 2 0 2 4
PET N2 4 1 2 7
PET, Positron emission tomography.
TABLE 5. Comparison of CT and pathologic N (pN) stages
(n  64)
pN0 pN1 pN2 Total
CT N0 53 4 3 60
CT N2 0 1 3 4CT, Computed tomography.
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TSThe lack of sensitivity cannot be explained solely by the
lack of uptake in the primary lesion because in only 2 of 6
cases of false-negative PET scans in the mediastinum were
the primary lesions inactive. Others have recently shown
that small microscopic nodal deposits will not be FDG
avid.16 In this report, although nodal deposits were not
measured, most of the node-positive patients had single-
level microscopic disease, which might explain the lack of
nodal sensitivity. Although the PET sensitivity in the me-
diastinum appears to be less than in previous reports, it is
comparable with the 61% sensitivity reported in the Z50
trial.11 Similarly, in another randomized trial of PET in
patients with stage I and II NSCLC, PET sensitivity for
detecting single-station nodal disease was 55%.17
Numerous PET studies have now been performed that
have used a reduction in unwarranted thoracotomies as their
end point.11,17 In our analysis there were no patients with
occult metastatic disease or nodal IIIB disease. Overall,
PET did not lead to a reduction in unwarranted thoracoto-
mies. However, given the retrospective nature of this study,
a prereferral bias cannot be excluded. Additionally, the 64
patients in this study were selected from 222 potential
candidates on the basis of a rigid set of selection criteria.
There are a number of limitations in this study. A number
of different nuclear and CT scanning facilities were used in
the evaluation of our patient population. However, studies
that did not fall within our quality criteria were excluded,
and all decisions in regard to further evaluation and treat-
ment were made by 2 surgeons. We therefore believe that
these data reflect the current practices of thoracic oncologists.
The role of PET scanning in the detection of occult
Figure 1. Survival for positron emission tomography (PET)–posi-
tive and PET-negative tumors. SUV, Standard uptake value.metastatic disease is not addressed by our work. This study,
1614 The Journal of Thoracic and Cardiovascular Surgery ● Decas previously noted, contains a highly select group of pa-
tients subject to inherent referral and selection biases. How-
ever, given the low reported incidence (0.5%-5%) of silent
metastases in this group of patients, it would seem unlikely
that PET would confer much advantage.18-21
In summary, although PET has been liberally applied for
the evaluation of many patients with lung cancer, it does not
appear to offer a clear advantage in patients with small,
peripherally located T1 or T2 tumors of less than 2 cm in
size. Furthermore, the use of PET in the evaluation of
clinically suspicious small, solitary pulmonary nodules ap-
pears to carry a high false-negative rate and should not be
the only basis for clinical management.
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